AOD9604 Research Guide | Signal Labs
AOD9604 is a synthetic fragment of human growth hormone's C-terminal lipolytic domain, studied for adipocyte biology and fatty acid metabolism research independently of IGF-1 or anabolic GH effects.
AOD9604 Research: Growth Hormone Fragment and Lipolytic Domain Biology
AOD9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment corresponding to the C-terminal lipolytic domain of human growth hormone, specifically residues 177-191 with an additional N-terminal tyrosine residue. Also described as Tyr-hGH177-191, it was developed to isolate the fat-metabolism effects of growth hormone while eliminating the anabolic, diabetogenic, and IGF-1-elevating effects of full-length GH receptor activation.
The Separation of GH's Functions
Full-length human growth hormone (191 amino acids) produces its effects through two primary mechanisms:
GH receptor binding (primarily N-terminal domain). The main GH receptor binding site involves residues primarily in the first 140 amino acids of the GH molecule. GH receptor activation drives hepatic IGF-1 production, anabolic effects in muscle and bone, anti-insulin metabolic effects, and retention of nitrogen.
Lipolytic C-terminal domain. The C-terminal region of GH (roughly residues 177-191) has been studied as having lipolytic activity through a mechanism distinct from GH receptor signalling. AOD9604 represents the isolated C-terminal lipolytic domain.
This separation of GH's anabolic and lipolytic functions into discrete domains was the research rationale for developing AOD9604 — a compound that could potentially be studied for fat metabolism biology without the broader metabolic effects of GH receptor activation.
Beta-3 Adrenergic Receptor Research
Published research has investigated AOD9604 in the context of beta-3 adrenergic receptor (ADRB3) stimulation in adipose tissue. ADRB3 is expressed predominantly in brown and white adipose tissue and activates lipolysis through cAMP-mediated PKA signalling leading to hormone-sensitive lipase (HSL) phosphorylation and activation.
Research has examined whether AOD9604-induced lipolysis in adipocyte cell models (3T3-L1, primary adipocytes) involves ADRB3 signalling or alternative pathways. Glycerol release assays and non-esterified fatty acid (NEFA) measurements are standard endpoints in AOD9604 lipolysis research.
Adipogenesis Research
Beyond lipolysis, AOD9604 has been examined in adipogenesis (fat cell differentiation) models. Research has investigated effects on:
- PPAR-gamma expression (master adipogenesis transcription factor)
- Lipid droplet accumulation during differentiation
- Lipogenic enzyme activity (fatty acid synthase, ACC)
- Fat cell marker gene expression
Clinical Research Context
AOD9604 progressed through Phase 2 clinical trials for obesity before development was discontinued, providing published pharmacokinetic data and dose-ranging information that supports its use as a research tool. Published Phase 2 data confirmed that AOD9604 does not significantly affect blood glucose, insulin, or IGF-1 levels at doses examined, distinguishing it pharmacologically from full-length GH.
Published Research References
Adipocyte Research Models
The primary in vitro research systems used with AOD9604 are:
3T3-L1 adipocytes. The 3T3-L1 mouse fibroblast cell line is the standard model for adipogenesis and lipolysis research. Differentiated 3T3-L1 adipocytes express functional beta-adrenergic receptors, HSL, and the complete lipolytic machinery. AOD9604 effects on fatty acid release (glycerol assay, NEFA assay) and lipid droplet content (Oil Red O staining) have been examined in this system. For differentiation studies, researchers examine effects of AOD9604 on the transition from preadipocytes to mature lipid-storing adipocytes.
Primary adipocytes. Freshly isolated primary adipocytes from rodent epididymal, inguinal, or mesenteric fat depots provide more physiologically relevant data than 3T3-L1 cells, with authentic depot-specific characteristics. NEFA release assays in primary adipocyte preparations are the standard endpoint for AOD9604 lipolysis research.
Human adipose tissue explants. For translational research, human adipose tissue biopsy explants allow examination of AOD9604 effects in authentic human adipose tissue containing adipocytes, stromal vascular fraction cells, and intact tissue architecture. Glycerol and NEFA release into culture media are the standard endpoints.
Comparison with Other Lipolytic Research Tools
| Tool | Mechanism | Receptor | Selectivity |
|---|---|---|---|
| AOD9604 | GH C-terminal domain | Proposed ADRB3 | White adipose |
| Isoproterenol | Beta-adrenergic agonist | ADRB1/2/3 | Non-selective |
| CL316,243 | Synthetic agonist | ADRB3-selective | Brown/white adipose |
| Forskolin | Adenylyl cyclase activator | cAMP elevation | Non-receptor specific |
| Full-length GH | GHR agonist | GHR | Multiple tissues + IGF-1 |
AOD9604's advantage as a research tool is studying lipolytic biology while avoiding IGF-1R cross-activation and the broad anabolic effects of full-length GH. Researchers examining adipose-specific lipolysis without confounding GH receptor biology use AOD9604 as the preferred GH-derived tool compound.
Published Research References
For laboratory and analytical research purposes only. Not for human or veterinary use.
Related research peptides: IGF-1 LR3 | Ipamorelin | Sermorelin Acetate
View AOD9604 product and buy →
Growth Hormone Biology: The Two-Domain Model
AOD9604's design is based on the two-domain model of GH biology — the observation that different regions of the 191 amino acid GH molecule mediate different biological effects through distinct receptors:
GH receptor binding domain (N-terminal, primarily residues 1-176): This region binds and activates the GHR (growth hormone receptor), a Class I cytokine receptor. GHR homodimerisation triggers JAK2 phosphorylation, STAT5b activation, and subsequent IGF-1 gene transcription in the liver. This is the anabolic, growth-promoting, diabetogenic arm of GH biology — responsible for IGF-1 elevation, muscle protein synthesis, and linear growth.
Lipolytic domain (C-terminal, residues 177-191): This region drives adipocyte lipolysis through a mechanism independent of the classical GHR/JAK2/STAT5b pathway. The lipolytic domain has been proposed to interact with beta-3 adrenergic receptors or with GHR at a different site than the N-terminal domain. AOD9604 represents the isolated C-terminal domain as a research tool.
The clinical rationale for this domain separation: a compound that retains GH's lipolytic effects without the diabetogenic and anabolic effects could theoretically address obesity-related metabolic disease without the adverse effects of full-length GH replacement therapy. Published Phase 2 clinical data confirmed AOD9604 does not elevate IGF-1 or affect glucose in healthy and obese subjects.
Beta-3 Adrenergic Receptor in Adipose Biology
The beta-3 adrenergic receptor (ADRB3) is expressed predominantly in adipose tissue — white and brown — where it mediates catecholamine-induced lipolysis. In white adipose tissue, ADRB3 activation raises cAMP via Gs, activating PKA, which phosphorylates and activates hormone-sensitive lipase (HSL) and perilipin A. HSL then cleaves triglycerides in lipid droplets, releasing non-esterified fatty acids (NEFA) and glycerol into the medium.
Research examining AOD9604's proposed beta-3 adrenergic receptor interaction uses: [35S]-GTPgammaS binding assays (measuring G-protein activation downstream of any GPCR, including ADRB3); ADRB3 radioligand binding displacement assays (competing AOD9604 with selective ADRB3 ligands like [125I]-cyanopindolol); and functional lipolysis assays in adipocytes comparing AOD9604 with selective ADRB3 agonist CL316,243 and non-selective beta-agonist isoproterenol as controls.
Frequently Asked Questions
Why did AOD9604 not progress to Phase 3 clinical trials despite Phase 2 success?
AOD9604 Phase 2 trials demonstrated safety and showed adipose tissue effects consistent with its proposed mechanism, but primary efficacy endpoints (body weight reduction in obese subjects) did not reach statistical significance versus placebo at the doses tested. The effect sizes observed were smaller than required for a commercially viable obesity treatment in an increasingly competitive metabolic medicine landscape, particularly as GLP-1 agonists were showing substantially larger weight reduction in the same period. Development was discontinued for weight management indications, though the published clinical dataset remains valuable as pharmacological reference data for laboratory research.
How does AOD9604 compare to GH fragment research using other growth hormone peptide regions?
Multiple C-terminal GH fragments have been studied: AOD9273 (hGH 177-191 without the additional Tyr), hGH 182-191, and other subregions have been compared for lipolytic potency. Published research by Ng et al. (FEBS Letters, 1990) characterised the minimal lipolytic domain of GH, establishing that residues 177-191 represent the core lipolytic pharmacophore. AOD9604 adds an additional N-terminal Tyr residue to this sequence to potentially improve activity. Systematic comparison of these fragments in parallel lipolysis assays allows characterisation of which residues are essential for lipolytic activity within the C-terminal domain.
Browse all Signal Labs research peptides | Peptide storage guide | Reconstitution guide